Related Experiment Video
Updated: Mar 30, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development
R V Overgaard1, S H Ingwersen1, C W Tornøe1
1Quantitative Clinical Pharmacology, Novo Nordisk A/S Søborg, Denmark.
Abstract:
This tutorial aims at promoting good practices for exposure-response (E-R) analyses of clinical endpoints in drug development. The focus is on practical aspects of E-R analyses to assist modeling scientists with a process of performing such analyses in a consistent manner across individuals and projects and tailored to typical clinical drug development decisions. This includes general considerations for planning, conducting, and visualizing E-R analyses, and how these are linked to key questions.
More Related Videos
11:38High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
Clinical Trials: Overview
Dose-Response Relationship: Overview
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...